Search Results

Oramed Pharmaceuticals Inc. announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

Oramed Pharmaceuticals Inc. announced that on September 21, 2023, Oramed and Scilex Holding Company entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note to Oramed.

Oramed Pharmaceuticals Inc. announced that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. to establish a joint venture based on Oramed’s oral drug delivery technology.

Oramed Pharmaceuticals Inc. announced the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023.

Oramed Pharmaceuticals Inc., announced that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials.

Oramed Pharmaceuticals Inc. announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association’s 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Oramed Pharmaceuticals Inc. today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.